





Reena Gogia Rastogi, MD, FAHS Barrow Neurological Institute at Phoenix Children's

Disclosure Statement

No disclosures



Learning Objectives

- Identify migraine as a prevalent and disabling neurological condition in children and adolescents
- Differentiate primary and secondary headache disorders to drive diagnosis in patients with presumed migraine
- Identify patients in need of imaging or subspecialist involvement
- Develop a plan for treating migraine acutely and reducing attack frequency through preventive measures





Migraine in Pediatrics

- 1. What is Migraine?
- 2. Migraine Epidemiology
- 3. Migraine Diagnosis
- 4. Education & Lifestyle Modification
- **5. Acute Treatment**
- 6. Migraine Prevention
- 7. Migraine and Contraception























Migraine in Pediatrics

1. What is Migraine?
























Migraine Definition

An **inherited disorder** characterized by attacks including a variety of **neurological** and **gastrointestinal** symptoms with or without severe headache.


Neurological symptoms may include sensory, vestibular, and cognitive disturbances.







Phases of a Migraine Attack



Premonitory symptoms

Hours to days

Fatigue

Cognitive changes

Neck stiffness

Yawning

Mood changes

Food cravings

Aura

5 to 60 mins

Fully reversible

neurological symptoms

Headache

2 to 72 hours

Throbbing pain

Phonophobia

Nausea

Osmophobia

Photophobia

Mood changes

Postdrome

24 to 48 hours

Fatigue

Cognitive changes


Neck stiffness

Adapted from Drugs. 2018;78:411-437.





Pathophysiology of Migraine







Migraine in Pediatrics

2. Migraine Epidemiology























Epidemiology

1 billion worldwide



Affects 1 in 11 Children



1 in 5 women



1 in 16 men



Headache. 2021;61:1021-1039; Lancet Neurol. 2018;17:954-976; Neurology. 2007;68:343-349; Curr Pain Headache Rep. 2013;17:341.





Episodic Syndromes that May be Associated with Migraine




Colic



Benign paroxysmal torticollis



Benign paroxysmal vertigo



Cyclic vomiting syndrome




Abdominal migraine

JAMA. 2013;309:1607-1612; Headache. 2019;59:988-1001; Neurology. 2012;79:1392-1396; Cephalalgia. 2018;38:1-211. Headache. 2021;61:231-243; Curr Opin Neurol. 2018;31:281-285. Pediatr Res. 2021;90:1044-1051.





Prevalence of Migraine Over Time










Prevalence of Migraine Compared to Other Common Pediatric Disorders




Curr Pain Headache Rep. 2013;17:341; health.gov. Accessed March 24, 2023; www.cdc.gov. Accessed March 24, 2023.





School-related Disability



JAMA Pediatr. 2021;175:522-524; JAMA Netw Open. 2021;4(7):e2114712.





Migraine in Pediatrics

3. Migraine Diagnosis























Migraine Diagnosis

ICHD-3 Criteria	Adult Specific	Peds Specific
Number of attacks	≥ 5	
Duration	4-72 hours	2-72
Location	Unilateral	Unilateral or bilateral
Description of pain	Pulsating	
Pain intensity	Moderate-severe	
Effect of routine physical activity	Aggravated by	
Nausea or vomiting	Yes	
Photophobia or phonophobia	Both	Inferred by behavior
Attributable	Not attributable to another disorder	

Cephalalgia. 2018;38:1-211.





Aura in Pediatric Patients with Migraine

- Prevalence is estimated at 15% to 30%
- Typically lasts 5 to 60 minutes
- May occur before or during the headache phase of migraine, or in isolation (without headache)
- Visual aura is most common
- Generalized blurry vision is common in migraine and often does meet criteria for aura



ICHD-3 Criteria for aura ・ロボストロ ・ファイン

Neurologic Clinics. 2009;27:481-501; https://youtu.be/qVFIcF9lyk8. Accessed March 31, 2023





Headache Red Flags



"SNOOPY" Mnemonic

Systemic symptoms (fever, myalgias, weight loss)

Secondary risk factors (immune deficiency, cancer, pregnancy)

Neurologic signs (papilledema, focal deficit, confusion, seizures)

Onset (sudden/thunderclap)

Older (new or progressive headache, especially over 50 years)

Pattern change (new symptoms in previously stable pattern)

Precipitants (Valsalva, position change, sexual activity)

Adapted from Adv Stud Med. 2003;3:550-555.





Clinical Pearls



RED FLAGS: Emergency Department

- Thunderclap headache (peak intensity in 60 seconds or less)
- Worst headache ever (but we've all had our worst headache ever)
- New onset intractable vomiting upon awakening
- Abnormal neurological (including fundoscopic) examination
- Provider concern (fever in immunocompromised patient, etc.)



- Patient younger than 6 years
- New onset or change in headache pattern (eg, new daily persistent headache)
- Side-locked Headache (eg, cluster headache)
- Headache consistently wakes patient up from sleep
- Valsalva-induced or positional headache

NDPH, new daily persistent headache Adapted from Adv Stud Med. 2003;3:550–555.






Pediatric Headache Imaging: The Debate

Yes!

- Concern for brain tumor
 - Second most common childhood malignancy
 - Incidence 2.8 4.5/100,000
- In youth with headache:
 - 2.5% had a CNS lesion requiring a change in management
 - 0.1% had completely normal exams
- Provides peace of mind



No!

- CT exposes children to radiation
- MRI is \$\$\$/exposure to gadolinium
- May require sedation/anesthesia
- Incidental findings are common (16.4%)
- Clinically meaningful findings required follow-up in 2.6% of healthy children
- In kids with > 6 months of headaches
 and a normal exam, risk for brain
 tumor is extremely low (0.01%)

Pedatr Radiol 2013;43:777-784; Headache. 2017;57:1601-1609; J Neuroradiol. 2019;40:1818.





Imaging in Headache Disorders





There is no necessity to do neuroimaging in patients with headaches consistent with migraine with a normal neurologic examination and no atypical features or red flags





Don't perform neuroimaging studies in patients with **stable headaches** that meet criteria for **migraine**

Don't perform **CT imaging** for headache when **MRI is** available, except in emergency settings (e.g., acute bleed)





Appropriateness Criteria® Headache — good resource for image selection in **specific clinical scenarios** (e.g., patients with known cancer)





Migraine in Pediatrics

4. Education & Lifestyle Modification























S.M.A.R.T. Habits for Migraine Management

Give specific sleep duration goals depending on age Sleep Keep sleep and waketimes consistent and limit screen time before bed Screen for insomnia and sleep apnea Eat at least 3 meals a day and snack as needed **Meals and Hydration** Give specific hydration goals Hydrate with every meal Limit unnecessary screen time **Activity** Aim for 30 minutes of physical activity 3-5 days per week Screen/address obesity Consider biofeedback programs, mindfulness apps Use deep breathing techniques Relaxation Practice yoga Screen for depression/anxiety Keep a headache log and track response **Triggers** Modify behavior as appropriate Limit or avoid caffeine/alcohol/tobacco use





Behavioral Therapies for Migraine


Biofeedback







Relaxation Training





- Supported by data
- Endorsed in US Headache Consortium guidelines
- Have long-lasting benefits
- Effective at all life stages
- Can be stand alone or combined with other therapies

Headache. 2021:1021-1039. Neurology. 2000;55:754-762.






Resources For Families

Headache Relief Guide





American Migraine Foundation





HeadacheReliefGuide.com. Accessed Mar 21, 2023. https://americanmigrainefoundation.org/. Accessed Mar 21, 2023.





Migraine in Pediatrics

5. Acute Treatment

























Step vs Stratified Care

STEP within or across attacks



STRATIFIED

by disease severity



JAMA. 2000;284:2599-605.





Acute Treatment: AAN/AHS Guideline

Classification	Agent	Dose
NSAIDs	Ibuprofen OS*	7.5-10mg/kg
	Sumatriptan/naproxen OT*	10/60 mg, 30/180 mg, 85/500 mg
	Zolmitriptan NS*	5 mg
Triptans	Sumatriptan NS*	20 mg
	Rizatriptan ODT†	5 mg or 10 mg
	Almotriptan OT [†]	12.5 mg
Dopamine antagonists	Prochlorperazine	0.15 mg/kg
	Promethazine	0.25-1 mg/kg
	Metoclopramide	0.13-0.15 mg/kg

^{*}Recommendations with high or moderate confidence in evidence; †Recommendations with low confidence in evidence. NS, nasal spray; NSAID, non-steroidal anti-inflammatory drugs; ODT, oral dissolving table; OS, oral solution; OT, oral tablet Neurology. 2019;93:487-499; Pediatr Emer Care. 2018;34:165–168; Maedica (Bucur). 2016;11:136–143.





Tips for Prescribing Triptans

Rule of 2

- Can take a 2nd dose after 2 hours
- No more than 2 doses in 24 hours
- Aim for 2 days per week or less

Serotonin Toxicity

 AHS position statement: currently available evidence does <u>not</u> support limiting the use of triptans with SSRIs or SNRIs

TIA, transient ischemic attack Headache. 2010;50:1089-1099.

Warn about potential side effects

- Tightness of face, neck, and chest
- Feeling hot, tingling
- Flu-like symptoms, fatigue, myalgias

Cautions and Contraindications

- Cardiac disease (eg, coronary artery disease, ischemic heart disease)
- Cerebrovascular disease (eg, stroke, TIA)
- Rare migraine subtypes (eg, hemiplegic migraine, migraine with brainstem aura)
- Uncontrolled HTN, severe hepatic impairment





Triptan Selection

Triptan	FDA Status	Formulation(s)	Comments
Rizatriptan	≥ 6 years old	Oral tablet/ODT	Use half dose in patients taking propranolol
Almotriptan	≥ 12 years old	Oral tablet	
Sumatriptan/ Naproxen	≥ 12 years old	Oral tablet	Max dosage is 1 tablet/24h
Zolmitriptan	≥ 12 years old	Oral tablet, ODT, NS	Only triptan nasal spray approved for use in pediatric patients
Sumatriptan	Not approved	Oral tablet, NS, NP, SC	Preferred during lactation
Eletriptan	Not approved	Oral tablet	Safest in lactation
Naratriptan	Not approved	Oral tablet	Longer half-life (6 hours)
Frovatriptan	Not approved	Oral tablet	Longer half-life (26h)

NP, nasal powder; NS, nasal spray; ODT, orally dissolving tablet; SC, subcutaneous Lancet Neurol. 2010;9:190-204; Headache. 2021;61:1021-1039; Medication specific package inserts.






Pediatric Migraine Management Plan

Tips for using the PedMAP include ensuring

- Teachers know about the plan
- Students know how to activate plan including when and where to go
- School staff understand who will give the medication and when



Headache. 2019;59:1871-1873.







Pearls: Acute Treatment

Nausea/vomiting	Combine with anti-nausea medication, or pursue non-oral route of administration (eg, nasal, subcutaneous)
NSAID not effective	Ensure a sufficient dose is taken at onset OR try a triptan
Triptan not effective	Try a different triptan, add an NSAID, and/or dopamine antagonist
Headache recurs after treatment	Add an NSAID and/or dopamine antagonist OR consider switching to a triptan with a long half-life (eg, naratriptan)
Excessive use	Start migraine prevention, discuss medication overuse
Failed therapy	Refer to Headache Specialist





Migraine in Pediatrics



























When to Prescribe Preventive Therapy









Nutraceuticals

Agent	Daily Dose	Notes
Riboflavin (vitamin B2)	50-200mg BID	Urine discoloration
Magnesium	9mg/kg/day BID	Diarrhea; chelated forms better tolerated
Coenzyme Q10	1-3 mg/kg/day or 100 mg BID	Generally well tolerated
Melatonin	0.3 mg/kg (up to 6mg)	Conflicting evidence

Petasites (butterbur) not currently recommended due to concerns about liver toxicity

Continuum (Minneap Minn). 2021;27:613-632. Medicine (Baltimore). 2019;98:e14099.





Pharmaceuticals: AAN/AHS Guidelines

Agent	Daily Dose	Notes
Topiramate*	2 mg/kg divided BID	Reproductive risk; folic acid supplement and contraception in patients of child-bearing potential
Amitriptyline*	1 mg/kg 2-4 hrs before bed	Black box warning for suicidality
Propranolol [†]	20-40 mg, TID	Contraindicated in asthma
Valproate [†]	40 mg/kg divided BID	Reproductive risk; folic acid supplement and contraception in patients of child-bearing potential
Cyproheptadine [‡]	0.2 – 0.4 mg/kg divided BID	Available in liquid form

^{*}Recommendations with high or moderate confidence in evidence; †Recommendations with low confidence in evidence; ‡while not mentioned in the AAN/AHS guidelines, some studies have noted potential efficacy; interventional clinical trials are needed to make appropriate recommendations.

Neurology. 2019;93:500-509; Pediatrics. 2021;147(6):e2020042101. Cochrane Review. 2017. Issue 3. CD010973. Sci Rep. 2021;11:452. J Pediatr Pharmacol Ther. 2008;13:17-24.





Childhood and Adolescent Migraine Prevention (CHAMP)

Neither topiramate nor amitriptyline demonstrated significant improvements vs placebo over 24 weeks in headache days or disability

CHAMP results support incorporating a multidisciplinary model including acute treatment, healthy lifestyle practices, and headache education

Some clinicians may use topiramate, amitriptyline, or nutraceuticals especially when treatment can provide additional benefit to comorbidities

N Engl J Med. 2017;376:115-124.





Tips for Use of Preventive Medication



Set Appropriate Expectations

- Goals: decrease attack frequency/disability, and improve response to acute treatment
- Minimum of <u>2 months at</u> target dose is common to see effect



Mitigate Side Effects and Address Comorbidities

- Start at a low dose
- Titrate slowly
- Consider which comorbidities can be co-treated



Preventive Medication Use is Not Forever

- Wean <u>3-6 months</u> after treatment goals met
- Discuss treatment course at initiation of preventive therapies

Headache. 2021;61:1021-1039.





Potential Treatment Options with a Headache Specialist

If treatment with nutraceuticals and pharmaceuticals fail, consider referral to a headache specialist

Novel Therapeutics and Procedures

- Research studies
- CGRP
- OnabotulinumtoxinA
- Nerve Blocks

Neuromodulation Devices (≥12 years)

- Remote electrical neuromodulation
- Non-invasive vagus nerve stimulation
- Single-pulse transcrainial magnetic stimulation





Migraine in Pediatrics



















7. Migraine and Contraception





Recommendations on CHCs Are Not Uniform in Migraine with Aura



Avoid CHCs in migraine with aura



CHCs contraindicated in migraine with aura



Low-dose estrogen may be prescribed in migraine with simple visual aura

CHC, combined hormonal contraception.

MMWR Recomm Rep. 2016;65(RR-3):1-104; Cephalalgia. 2000;20:155-6; Obstet Gynecol. 2019:133(2):396-9.





Combined Hormonal Contraceptives for Preventive Treatment of Migraine Without Aura

Combined estrogen-progestin

- Pills: monophasic low-dose estrogen EE 10-20 mcg
 - Can be taken continuously, skipping inactive pills
- Vaginal Rings: EE 13-15 mcg released daily over 3 weeks

Changes in headache pattern

- New onset of aura, increased frequency/severity, consider
 - Nonhormonal contraception
 - Progestin-only contraceptives

EE, ethinyl estradiol

Headache. 2007;47:27-37; Headache. 2012;52:1246-53; CDC. 2016; 65:1-104.






Contraception Options: Migraine With Aura

Progestin-Only



Pill
Taken daily without breaks



Implant



Intrauterine Device



Injectable Progestin

Non-Hormonal



Intrauterine System





Lower Doses of Estrogen are Associated with a Lower Risk of Ischemic Stroke

Dose	Odds Ratio for Ischemic Stroke
Progestin-only pills	0.9-1.0
EE 20 mcg	1.7
EE 30-40 mcg	1.6-2.7
EE 50 mcg	2.9-4.8

EE, ethinyl estradiol Headache. 2018;58:5-21.





In Summary


- Migraine is as prevalent as other common childhood conditions
- Diagnose early and rule out secondary headache
- Provide acute treatment and a plan for school with clear direction and specific goals
- Use behavioral, nutraceutical, or medical treatment to prevent headache and limit disability





Online Resource Library

First Contact – Headache in Primary Care provides free educational resources to help you identify and treat migraine and other headache disorders.





Migraine Management

Flowchart









Patient Guide Library

Official Podcast











Authors

The following American Headache Society members collaborated to produce the First Contact – Migraine in Pediatrics PowerPoint presentation:

- Lauren Doyle Strauss, DO, FAHS, Assistant Professor, Pediatric Neurology
- Jessica Gautreaux, MD, FAHS Associate Professor of Neurology and Pediatrics
- Hannah Shapiro, MD, Pediatric Neurologist
- Marielle Kabbouche Samaha, MD, Professor of Child Neurology & Headache Medicine
- Noam Lax, MD, Pediatric Neurologist/Headache Specialist
- Andrea Loeffert, DO, Assistant Professor of Pediatrics
- Sarah Robinson, MD, Clinical Adjunct Faculty, Pediatrics
- Adam Sprouse Blum, MD, PhD, Family Medicine Specialist
- Scott Turner, DNP, Assistant Professor Pediatric Neurology





Evaluation

Please share your feedback



Scan for immediate access



